Ritu Shrestha
Overview
Explore the profile of Ritu Shrestha including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
33
Citations
709
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Shi H, Fu Y, Kodyte V, Andreas A, Sachla A, Miller K, et al.
Nat Commun
. 2025 Mar;
16(1):2204.
PMID: 40044701
Bacillus subtilis MntR is a dual regulatory protein that responds to heightened Mn availability in the cell by both repressing the expression of uptake transporters and activating the expression of...
2.
Shi H, Fu Y, Kodyte V, Andreas A, Sachla A, Miller K, et al.
Res Sq
. 2024 Jul;
PMID: 39070638
The manganese transport regulator (MntR) from is a dual regulatory protein that responds to heightened Mn availability in the cell by both repressing the expression of uptake transporters and activating...
3.
Shi H, Fu Y, Kodyte V, Andreas A, Sachla A, Miller K, et al.
bioRxiv
. 2024 Jul;
PMID: 38979284
The manganese transport regulator (MntR) from is a dual regulatory protein that responds to heightened Mn availability in the cell by both repressing the expression of uptake transporters and activating...
4.
Cao L, Bridle K, Shrestha R, Prithviraj P, Crawford D, Jayachandran A
Int J Mol Sci
. 2022 Feb;
23(3).
PMID: 35163489
Gallbladder cancer (GBC) is one of the most common and aggressive biliary tract cancers with a dismal prognosis. Ongoing clinical trials are evaluating a few selected immune checkpoint inhibitors (ICIs)...
5.
Shrestha R, Bridle K, Cao L, Crawford D, Jayachandran A
Curr Oncol
. 2021 Jul;
28(3):2150-2172.
PMID: 34208001
Sorafenib, an oral multi-tyrosine kinase inhibitor, has been the first-line therapy for the treatment of patients with advanced HCC, providing a survival benefit of only three months in approximately 30%...
6.
Shrestha R, Bridle K, Crawford D, Jayachandran A
Int J Med Sci
. 2021 Jun;
18(12):2466-2479.
PMID: 34104078
Hepatocellular carcinoma (HCC) is the most common type of primary liver cancer with a high mortality rate. Epithelial-to-mesenchymal transition (EMT) confers cancer cells with immune evasive ability by modulating the...
7.
Cao L, Prithviraj P, Shrestha R, Sharma R, Anaka M, Bridle K, et al.
J Clin Med
. 2021 Jun;
10(10).
PMID: 34069452
Cholangiocarcinoma (CCA) is a hepatobiliary malignancy associated with steadily increasing incidence and poor prognosis. Ongoing clinical trials are assessing the effectiveness and safety of a few immune checkpoint inhibitors (ICIs)...
8.
Shrestha R, Prithviraj P, Bridle K, Crawford D, Jayachandran A
J Clin Med
. 2021 Apr;
10(9).
PMID: 33925488
Hepatocellular carcinoma (HCC) is the most common type of primary hepatic malignancy. HCC is one of the leading causes of cancer deaths worldwide. The oral multi-tyrosine kinase inhibitor Sorafenib is...
9.
Engevik M, Danhof H, Shrestha R, Chang-Graham A, Hyser J, Haag A, et al.
Gut Microbes
. 2020 Aug;
12(1):1788898.
PMID: 32804011
Antibiotic resistance is one of the world's greatest public health challenges and adjunct probiotic therapies are strategies that could lessen this burden. infection (CDI) is a prime example where adjunct...
10.
Shrestha R, Bridle K, Crawford D, Jayachandran A
Mol Med Rep
. 2020 Apr;
21(4):1849-1860.
PMID: 32319631
Hepatocellular carcinoma (HCC) is the fastest growing cause of cancer‑related deaths globally. Epithelial‑to‑mesenchymal transition (EMT) is a cellular process that confers HCC tumor cells with the ability to evade the...